Telomir Pharmaceuticals (TELO) said Wednesday it has obtained $3 million in equity financing through a direct investment from its largest shareholder The Bayshore Trust.
The deal, which involved the purchase of 1 million Telomir restricted shares at $3 apiece, was structured as a straight stock transaction with no warrants, discounts, and convertible features, the company said.
Telomir said the investment will fund its upcoming submission of its investigational new drug application for a rare disease indication.
Shares of the company fell 3.1% in recent trading.
Price: 2.22, Change: -0.07, Percent Change: -3.10
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。